Goldman Sachs Group Inc. announced Bayer (ETR:BAYN), boosting its stock price target to 129.00EUR today
- Updated: September 24, 2016
In a report issued Thursday September 22, 2016 Goldman Sachs Group Inc. bumped up the target of Bayer (ETR:BAYN) to 129.00EUR stating a potential upside of 0.41%.
Previously on 9/21/2016, Societe Generale reported on Bayer (ETR:BAYN) increased the target price from 0.00EUR to 105.00EUR. At the time, this indicated a possible upside of 0.15%.
Yesterday Bayer (ETR:BAYN) traded 0.00% even at 91.46EUR. The company’s 50-day moving average is 0.04EUR and its 200-day moving average is 0.03EUR. The last closing price is up -4.07% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time period. 0 shares of the stock traded hands, down from an average trading volume of 215
See Chart Below
Bayer has a 52 week low of 0.01EUR and a 52 week high of 0.08EUR The company’s market cap is currently 0 EUR.
General Information About Bayer (ETR:BAYN)
Bayer AG is a life science company. The Company's segments are Pharmaceuticals, Consumer Health, Crop Science, Animal Health and Covestro. The Pharmaceuticals segment is engaged in the development of prescription pharmaceuticals; contraceptives, and medical products, such as injection systems and contrast agents for diagnostic procedures. The Consumer Health segment is engaged in the development of over-the-counter medications, dermatology products and nutritional supplements. The Crop Science segment is engaged in the development of product portfolio in the areas of seeds and plant traits, crop protection, home and garden, the green industry and nonagricultural pest control. The Animal Health segment is engaged in the development of veterinary medicines and animal grooming products. Covestro is engaged in the development of raw materials for polyurethanes; polycarbonate resins and sheets; raw materials for coatings, adhesives and sealants; and selected chemical intermediates.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.